Body&Fit to Utilize Lonza’s Comprehensive Capsule and Specialty Ingredients Portfolio to Expand Product Offering

December 17, 2020
  • Glanbia Performance Nutrition’s direct-to-customer division Body&Fit to utilize Lonza’s DUOCAP® capsule technology
  • Body&Fit plans to launch new products featuring Lonza’s capsule and specialty ingredients, including UC-II® and MuscleGuard™ formulations to target the consumer health and nutrition segment, with a focus on joint health, immunity support and beauty

Quote from Roel van de Put, Business Development Manager, Lonza:

“This collaboration with Body&Fit is a perfect showcase of our combined expertise in providing high-quality sports nutrition and dietary supplements in unique dose delivery formats. We are excited to work with Body&Fit to help consumers live a fitter and healthier lifestyle with new and innovative nutrition products.”

Quote from Szabina Pál, Product Development Manager for the tablet and capsule portfolio at Body&Fit:

“Body&Fit, just like Lonza, is constantly looking for unique solutions to bring truly innovative products to the market. Lonza’s cutting-edge technologies, premium ingredients and forward-thinking concepts are the perfect fit with our vision, mission and business model. We are very excited to combine our strengths to maximize our potential.”

Basel, Switzerland, 17 December 2020 – Body&Fit, Glanbia Performance Nutrition’s direct-to-consumer brand, and Lonza today announced a collaboration to expand  Body&Fit’s nutrition, supplements and dietary solutions globally utilizing Lonza’s DUOCAP® capsule portfolio and specialty nutrition ingredients.

As a regional leader in sports nutrition and dietary supplements, Body&Fit is dedicated to providing consumers with products to enhance their sports performance and healthy lifestyle goals for the past 25 years. This latest partnership with Lonza, a complete solutions provider for the nutritional industry, helps fulfill Body&Fit’s promise to help consumers meet their fitness goals.

With a capsule-in-a capsule design, Lonza’s DUOCAP® technology provides a unique delivery format enabling combined dosing of ingredients that may otherwise be incompatible.

The first two DUOCAP® products for Body&Fit, Beauty Skin Duo and Pro B Duo have already been launched. Both products using titanium dioxide (TiO2) -free inner capsule, tapping into the clean label consumer trend.

Body&Fit has plans to launch three additional products for immunity health and sleep, mood and anxiety in early 2021. All three supplements will feature Lonza’s DUOCAP® capsule technology.

Additionally, Body&Fit is developing a premium joint health and support supplement, utilizing Lonza’s world-class TiO2-free hard capsules portfolio as well as patented ingredient UC-II® undenatured type II collagen, which is clinically proven to significantly improve mobility and joint comfort. This will make Body&Fit one of the first online direct-to-consumer (D2C) brands to provide their consumers with the latest solution for joint health.

A key element of the collaboration is the exclusive development of an intra-workout product featuring one of Lonza’s latest ingredients, Muscleguard™ formulation, which is a unique blend that delivers pre-, intra- and post-workout support.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG. 

About Body&Fit

Body&Fit supplies sports, lifestyle and fitness performance products all over the world. Founded in the Netherlands, Body&Fit has been in the sports nutrition, supplement and dietary product business since 1995 and is now a proud market leader in fitness nutrition. In 2017, Body&Fit joined Glanbia Performance Nutrition (GPN), the global performance nutrition and lifestyle brand business. 

With a rich heritage in the nutrition industry, GPN is a world leader in innovation and new product development and is devoted to performance at all activity levels and constant learning advancement in nutrition. GPN is part of Glanbia, a global nutrition group whose purpose is delivering better nutrition for every step of life’s journey. Body&Fit is a vital pillar of GPN as a Direct to Consumer (DTC) business, supplying the full range of products and services across GPN’s extensive brand portfolio, which includes Optimum Nutrition, SlimFast, Amazing Grass, Nutramino, BSN, Isopure, think! and ABB.

Committed to inspire people all over the world to enjoy fitter and  healthier lives, Body&Fit is taking every step they can to support their people and worldwide consumer base, like staying on top of the latest developments in performance nutrition and bringing products to all consumers by opening new webshops across the world. Find out more at

Lonza Contact Details

Dr. Sanna Fowler 
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929

Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel +41 79 421 1609

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. 

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.